[1] |
郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019,41(1):19-28.
|
[2] |
段纪俊,严亚琼,杨念念,等. 中国恶性肿瘤发病与死亡的国际比较分析[J]. 中国医学前沿杂志(电子版),2016,8(7):17-23.
|
[3] |
CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
|
[4] |
NAKAGAWA H,WARDELL C P,FURUTA M,et al.Cancer whole-genome sequencing:present and future[J]. Oncogene,2015,34(49):5943-5950.
|
[5] |
COOMBS C C,ZEHIR A,DEVLIN S M,et al.Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes[J]. Cell Stem Cell,2017,21(3):374-382.
|
[6] |
COOMBS C C,GILLIS N K,TAN X,et al.Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays[J]. Clin Cancer Res,2018,24(23):5918-5924.
|
[7] |
BOUAOUN L,SONKIN D,ARDIN M,et al.TP53 variations in human cancers:new lessons from the IARC TP53 database and genomics data[J]. Hum Mutat,2016,37(9):865-876.
|
[8] |
ZHANG Y L,YUAN J Q,WANG K F,et al.The prevalence of EGFR mutation in patients with non-small cell lung cancer:a systematic review and meta-analysis[J]. Oncotarget,2016,7(48):78985-78993.
|
[9] |
程亚楠,叶英楠,董莉,等. 靶向高通量测序在非小细胞肺癌中的临床应用[J]. 中国肿瘤临床,2018,45(11):582-588.
|
[10] |
MAZIÈRES J,PETERS S,LEPAGE B,et al. Lung cancer that harbors an HER2 mutation:epidemiologic characteristics and therapeutic perspectives[J]. J Clin Oncol,2013,31(16):1997-2003.
|
[11] |
ADDERLEY H,BLACKHALL F H,LINDSAY C R.KRAS-mutant non-small cell lung cancer:converging small molecules and immune checkpoint inhibition[J]. EBioMedicine,2019,41:711-716.
|
[12] |
VANDERLAAN P A,RANGACHARI D,MOCKUS S M,et al.Mutations in TP53,PIK3CA,PTEN and other genes in EGFR mutated lung cancers:correlation with clinical outcomes[J]. Lung Cancer,2017,106:17-21.
|
[13] |
LABBÉ C,CABANERO M,KORPANTY G J,et al.Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer(NSCLC)[J]. Lung Cancer,2017,111:23-29.
|